VI 25 mcg OD (N = 115) | SAL 50 mcg BD (N = 116) | Placebo (N = 116) | |
---|---|---|---|
Day 1 | |||
N | 115 | 116 | 113 |
Number (%) patients achieving threshold increasea | 65 (57) | 59 (51) | 36 (32) |
Hazard ratio vs. placebo | 2.358 | 1.750 | NA |
95% CI | (1.542 – 3.606) | (1.136 – 2.696) | |
Day 84 | |||
N | 101 | 100 | 96 |
Number (%) patients achieving threshold increasea | 57 (56) | 54 (54) | 51 (53) |
Hazard ratio vs. placebo | 0.993 | 0.911 | NA |
95% CI | (0.659 – 1.495) | (0.604 – 1.374) |